Clinical Pharmacology Details


STREPTOKINASE


View Drug Forms

Indications & Dose:

Acute myocardial infarction



Adult: 1 500 000 units, to be initiated within 12 hours of symptom onset, dose to be given over 60 minutes


Deep-vein thrombosis


Pulmonary embolism


Acute arterial thromboembolism


Central retinal venous or arterial thrombosis l



Adult: 250 000 units, dose to be given over 30 minutes, then 100 000 units every 1 hour for up to 12–72 hours, duration is adjusted according to condition with monitoring of clotting parameters (consult product literature)


Children


Not recommended.


 

Contraindications:

Active internal bleeding; recent (within 2 mo) CVA; intracranial or intraspinal surgery, intracranial neoplasm; severe uncontrolled hypertension

Side Effects:

CNS: Fever, headache


CV: Hypertension, reperfusion dysrhythmias


EENT: Periorbital edema


GI: Nausea, vomiting


HEME: Anemia, bleeding (GI, GU, intracranial, retroperitoneal, surface)


RESP: Altered respirations, bronchospasm, lion-cardiogenic pulmonary edema, shortness of breath


SKIN: Flushing, itching, phlebitis at IV INF site, rash, urticaria


MISC: Chills, sweating


 

Cautions:

Precautions:

Recent (within 10 days) surgery, obstetrical delivery, organ biopsy, trauma including CPR; high likelihood of left heart thrombus (e.g., mitral stenosis with atrial fibrillation); subacute bacterial endocarditis; hemostatic defects; age >75 yr; diabetic hemorrhagic retinopathy; septic thrombophlebitis or infected occluded AV cannula at seriously infected site; recent streptococcal infection; repeat administration (between 5 days and 12 mo of prior streptokinase), possibility of preexisting thrombus as in abdominal aneurysm or enlarged left atrium with atrial fibrillation (risk of dissolution of clot and subsequent embolization), recent of concurrent anticoagulant therapy


. Pregnancy; no data available for breast feeding

Interaction:

Drugs Heparin, oral anticoagulants, drugs that alter platelet function (i.e., aspirin, dipyridamole, ahciximab, eptifibitide, tirofiben): May increase the risk of bleeding


 

Warnings:

Adverse Effects:

Lactations:

Special Precautions:

Counselling:

Side Effects Or Adverse Reactions:

Patient And Carer Advice: